CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis

Annals of Neurology

Volumn 80, Issue 2, 2016, Pages 294-300

  Gerdes, Lisa Ann ^a   Held, Kathrin ^a   Beltrán, Eduardo ^a   Berking, Carola ^b   Prinz, Jörg C ^b   Junker, Andreas ^c,d   Tietze, Julia K ^b   Ertl Wagner, Birgit ^a   Straube, Andreas ^a   Kümpfel, Tania ^a   Dornmair, Klaus ^a   Hohlfeld, Reinhard ^a,e  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e Technische Universität München Munich Cluster for Systems Neurology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BINIMETINIB; CARBOPLATIN; DACARBAZINE; FLUORODEOXYGLUCOSE; GLUCOCORTICOID; IPILIMUMAB; NRAS Q61R PROTEIN; PACLITAXEL; PROTEIN; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN BIOPSY; BRAIN DAMAGE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID CYTOLOGY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORTI ORGAN; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPOPHYSITIS; HYPOPITUITARISM; LYMPH NODE METASTASIS; MALE; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NEXT GENERATION SEQUENCING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STEREOTACTIC BIOPSY; T LYMPHOCYTE RECEPTOR GENE;

EID: 84981250350     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24715     Document Type: Article

References (26)

1. Gourraud PA, Harbo HF, Hauser SL, Baranzini SE. The genetics of multiple sclerosis: an up-to-date review. Immunol Rev 2012;248:87–103.
2. Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol 2015;15:545–558.
3. Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest 2012;122:1180–1188.
4. Sawcer S, Franklin RJ, Ban M. Multiple sclerosis genetics. Lancet Neurol 2014;13:700–709.
5. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011;476:214–219.
6. Beecham AH, Patsopoulos NA, Xifara DK, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013;45:1353–1360.
7. Shugay M, Britanova OV, Merzlyak EM, et al. Towards error-free profiling of immune repertoires. Nat Methods 2014;11:653–655.
8. Lammert A, Schneider HJ, Bergmann T, et al. Hypophysitis caused by ipilimumab in cancer patients: hormone replacement or immunosuppressive therapy. Exp Clin Endocrinol Diabetes 2013;121:581–587.
9. Okuda DT, Mowry EM, Beheshtian A, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 2009;72:800–805.
10. Lucchinetti C, Brück W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707–717.
11. Gettings EJ, Hackett CT, Scott TF. Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma. Mult Scler 2015;21:670.
12. Cao Y, Nylander A, Ramanan S, et al. CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment. Neurology 2016;86:1553–1556.
13. Kyi C, Carvajal RD, Wolchok JD, Postow MA. Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer 2014;2:35.
14. Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 2011;11:852–863.
15. Schildberg FA, Klein SR, Freeman GJ, Sharpe AH. Coinhibitory pathways in the B7-CD28 ligand-receptor family. Immunity 2016;44:955–972.
16. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015;348:56–61.
17. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30:2691–2697.
18. Klocke K, Sakaguchi S, Holmdahl R, Wing K. Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood. Proc Natl Acad Sci U S A 2016;113:E2383–E2392.
19. Paterson AM, Lovitch SB, Sage PT, et al. Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity. J Exp Med 2015;212:1603–1621.
20. Karandikar NJ, Vanderlugt CL, Walunas TL, et al. CTLA-4: a negative regulator of autoimmune disease. J Exp Med 1996;184:783–788.
21. Perrin PJ, Maldonado JH, Davis TA, et al. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J Immunol 1996;157:1333–1336.
22. Steinman L. A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: a tale of smart bombs and the infantry. Proc Natl Acad Sci U S A 1996;93:2253–2256.
23. Schlager C, Korner H, Krueger M, et al. Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid. Nature 2016;530:349–353.
24. Hohlfeld R, Dornmair K, Meinl E, Wekerle H. The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4 + T lymphocytes as pathogenic effectors and therapeutic targets. Lancet Neurol 2016;15:198–208.
25. Hohlfeld R, Dornmair K, Meinl E, Wekerle H. The search for the target antigens of multiple sclerosis, part 2: CD8 + T cells, B cells, and antibodies in the focus of reverse-translational research. Lancet Neurol 2016;15:317–331.
26. Viglietta V, Bourcier K, Buckle GJ, et al. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology 2008;71:917–924.